Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells

American Journal of Respiratory Cell and Molecular Biology

Volumn 53, Issue 5, 2015, Pages 689-702

  Statt, Sarah ^a   Ruan, Jhen Wei ^b   Hung, Li Yin ^a   Chang, Ching Yun ^a   Huang, Chih Ting ^b   Lim, Jae Hyang ^c   Li, Jian Dong ^d   Wu, Reen ^a   Kao, Cheng Yuan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c Ewha Womans University School of Medicine   (South Korea)

^d GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Airway epithelium; Cholesterol; Pneumolysin; Pneumonia; Simvastatin

Indexed keywords

ALPHA HEMOLYSIN; PNEUMOLYSIN; PRAVASTATIN; SIMVASTATIN; BACTERIAL PROTEIN; BACTERIAL TOXIN; HEMOLYSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; STAPHYLOCOCCAL ALPHA-TOXIN; STREPTOLYSIN;

ARTICLE; BACTERIAL INFECTION; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM CELL; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; PROTEIN SYNTHESIS; STREPTOCOCCUS PNEUMONIAE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; INNATE IMMUNITY; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG; MOUSE; PATHOLOGY; PRIMARY CELL CULTURE; RESPIRATORY TRACT MUCOSA; STAPHYLOCOCCUS AUREUS; TRANSFORMED CELL LINE;

ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CELL LINE, TRANSFORMED; EPITHELIAL CELLS; HEMOLYSIN PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNITY, INNATE; INJECTIONS, INTRAPERITONEAL; LUNG; MICE; MICE, INBRED C57BL; PRAVASTATIN; PRIMARY CELL CULTURE; RESPIRATORY MUCOSA; SIMVASTATIN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS;

EID: 84930624257     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2014-0391OC     Document Type: Article

References (61)

1. Denny FW, Loda FA. Acute respiratory infections are the leading cause of death in children in developing countries. Am J Trop Med Hyg 1986; 35:1-2.
2. Berkley JA, Lowe BS, Mwangi I, Williams T, Bauni E, Mwarumba S, Ngetsa C, Slack MP, Njenga S, Hart CA, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 2005;352: 39-47.
3. Irfan M, Farooqi J, Hasan R. Community-acquired pneumonia. Curr Opin Pulm Med 2013;19:198-208.
4. Low DE, Pichichero ME, Schaad UB. Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance. Clin Pediatr (Phila) 2004;43:135-151.
5. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422.
6. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-213.
7. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in America and gaps in patient education (usage): An internet-based survey of 10, 138 current and former statin users. J Clin Lipidol 2012;6:208-215.
8. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627.
9. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-121.
10. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
11. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-2021.
12. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006;333:999.
13. Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, Oelert H, Sibelius U, Grandel U, Grimminger F, Seeger W, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alphatoxin. Circulation 2002;106:2104-2110.
14. Burns EM, Smelser LK, Then JE, Stankiewicz TE, Kushdilian M, McDowell SA, Bruns HA. Short term statin treatment improves survival and differentially regulates macrophage-mediated responses to Staphylococcus aureus. Curr Pharm Biotechnol 2013; 14:233-241.
15. Chow OA, von Kockritz-Blickwede M, Bright AT, Hensler ME, Zinkernagel AS, Cogen AL, Gallo RL, Monestier M, Wang Y, Glass CK, et al. Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 2010;8:445-454.
16. Parihar SP, Guler R, Lang DM, Suzuki H, Marais AD, Brombacher F. Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeria-induced phagosomal escape. PLoS One 2013;8:e75490.
17. Ryu JH, Kim CH, Yoon JH. Innate immune responses of the airway epithelium. Mol Cells 2010;30:173-183.
18. Vareille M, Kieninger E, Edwards MR, Regamey N. The airway epithelium: soldier in the fight against respiratory viruses. Clin Microbiol Rev 2011;24:210-229.
19. Alouf JE. Pore-forming bacterial protein toxins: An overview. Curr Top Microbiol Immunol 2001;257:1-14.
20. Los FC, Randis TM, Aroian RV, Ratner AJ. Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol Rev 2013;77: 173-207.
21. Benazet JD, Bischofberger M, Tiecke E, Goncalves A, Martin JF, Zuniga A, Naef F, Zeller R. A self-regulatory system of interlinked signaling feedback loops controls mouse limb patterning. Science 2009;323:1050-1053.
22. Parker MW, Feil SC. Pore-forming protein toxins: from structure to function. Prog Biophys Mol Biol 2005;88:91-142.
23. Berry AM, Yother J, Briles DE, Hansman D, Paton JC. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 1989;57:2037-2042.
24. Rubins JB, Charboneau D, Paton JC, Mitchell TJ, Andrew PW, Janoff EN. Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest 1995;95:142-150.
25. Marriott HM, Mitchell TJ, Dockrell DH. Pneumolysin: A double-edged sword during the host-pathogen interaction. Curr Mol Med 2008;8: 497-509.
26. Cockeran R, Anderson R, Feldman C. Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease. Arch Immunol Ther Exp (Warsz) 2005;53: 189-198.
27. Witzenrath M, Gutbier B, Hocke AC, Schmeck B, Hippenstiel S, Berger K, Mitchell TJ, de los Toyos JR, Rosseau S, Suttorp N, et al. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med 2006;34:1947-1954.
28. Lim JH, Stirling B, Derry J, Koga T, Jono H, Woo C-H, Xu H, Bourne P, Ha U-H, Ishinaga H, et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 2007;27:349-360.
29. Lucas R, Yang G, Gorshkov BA, Zemskov EA, Sridhar S, Umapathy NS, Jezierska-Drutel A, Alieva IB, Leustik M, Hossain H, et al. Protein kinase C-a and arginase I mediate pneumolysin-induced pulmonary endothelial hyperpermeability. Am J Respir Cell Mol Biol 2012;47: 445-453.
30. Bubeck Wardenburg J, Bae T, Otto M, DeLeo FR, Schneewind O. Poring over pores: A-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 2007;13:1405-1406.
31. Bubeck Wardenburg J, Patel RJ, Schneewind O. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun 2007;75:1040-1044.
32. Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008;205:287-294.
33. Hu CM, Fang RH, Luk BT, Zhang L. Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol 2013;8:933-938.
34. Thai P, Statt S, Chen CH, Liang E, Campbell C, Wu R. Characterization of a novel long noncoding RNA, SCAL1, induced by cigarette smoke and elevated in lung cancer cell lines. Am J Respir Cell Mol Biol 2013;49:204-211.
35. Horani A, Nath A, Wasserman MG, Huang T, Brody SL. Rho-associated protein kinase inhibition enhances airway epithelial basal-cell proliferation and lentivirus transduction. Am J Respir Cell Mol Biol 2013;49:341-347.
36. Kao C-Y, Chen Y, Thai P, Wachi S, Huang F, Kim C, Harper RW, Wu R. IL-17 markedly up-regulates b-defensin-2 expression in human airway epithelium via JAK and NF-kB signaling pathways. J Immunol 2004;173:3482-3491.
37. Kao C-Y, Kim C, Huang F, Wu R. Requirements for two proximal NF-kB binding sites and IkB-z in IL-17A-induced human b-defensin 2 expression by conducting airway epithelium. J Biol Chem 2008;283: 15309-15318.
38. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering: Are they clinically relevant? Eur Heart J 2003;24:225-248.
39. Castanho MA, Coutinho A, Prieto MJ. Absorption and fluorescence spectra of polyene antibiotics in the presence of cholesterol. J Biol Chem 1992;267:204-209.
40. Korchev YE, Bashford CL, Pederzolli C, Pasternak CA, Morgan PJ, Andrew PW, Mitchell TJ. A conserved tryptophan in pneumolysin is a determinant of the characteristics of channels formed by pneumolysin in cells and planar lipid bilayers. Biochem J 1998;329: 571-577.
41. Park DS, So HS, Lee JH, Park HY, Lee YJ, Cho JH, Yoon KH, Park C, Yun K, Park R. Simvastatin treatment induces morphology alterations and apoptosis in murine cochlear neuronal cells. Acta Otolaryngol 2009;129:166-174.
42. Menter DG, Ramsauer VP, Harirforoosh S, Chakraborty K, Yang P, Hsi L, Newman RA, Krishnan K. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One 2011;6:e28813.
43. Chen J-C, Wu M-L, Huang K-C, Lin W-W. HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression. Cardiovasc Res 2008;80: 138-150.
44. Idone V, Tam C, Goss JW, Toomre D, Pypaert M, Andrews NW. Repair of injured plasma membrane by rapid Ca21-dependent endocytosis. J Cell Biol 2008;180:905-914.
45. Rodenak Kladniew B, Polo M, Montero Villegas S, Galle M, Crespo R, Garcia de Bravo M. Synergistic antiproliferative and anticholesterogenic effects of linalool, 1, 8-cineole, and simvastatin on human cell lines. Chem Biol Interact 2014;214:57-68.
46. Wu Y, Lv J, Feng D, Jiang F, Fan X, Zhang Z, Yin R, Xu L. Restoration of alveolar type II cell function contributes to simvastatin-induced attenuation of lung ischemia-reperfusion injury. Int J Mol Med 2012; 30:1294-1306.
47. Brown AO, Mann B, Gao G, Hankins JS, Humann J, Giardina J, Faverio P, Restrepo MI, Halade GV, Mortensen EM, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog 2014;10: E1004383.
48. Rosch JW, Boyd AR, Hinojosa E, Pestina T, Hu Y, Persons DA, Orihuela CJ, Tuomanen EI. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest 2010;120:627-635.
49. Backman JT, Kyrklund C, Kivisto KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-129.
50. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjorndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 2004;59: 879-882.
51. Kim J, Ahn BJ, Chae HS, Han S, Doh K, Choi J, Jun YK, Lee YW, Yim DS. A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia. Basic Clin Pharmacol Toxicol 2011;109:156-163.
52. Medina RJ, O'Neill CL, Devine AB, Gardiner TA, Stitt AW. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS One 2008;3:e2584.
53. Habets MG, Rozen DE, Brockhurst MA. Variation in Streptococcus pneumoniae susceptibility to human antimicrobial peptides may mediate intraspecific competition. Proc Biol Sci 1743;2012: 3803-3811.
54. Houldsworth S, Andrew PW, Mitchell TJ. Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infect Immun 1994;62:1501-1503.
55. Huffman DL, Abrami L, Sasik R, Corbeil J, van der Goot FG, Aroian RV. Mitogen-activated protein kinase pathways defend against bacterial pore-forming toxins. Proc Natl Acad Sci USA 2004;101: 10995-11000.
56. Bischof LJ, Kao C-Y, Los FCO, Gonzalez MR, Shen Z, Briggs SP, van der Goot FG, Aroian RV. Activation of the unfolded protein response is required for defenses against bacterial pore-forming toxin in vivo. PLoS Pathog 2008;4:e1000176.
57. Bellier A, Chen C-S, Kao C-Y, Cinar HN, Aroian RV. Hypoxia and the hypoxic response pathway protect against pore-forming toxins in C. elegans. PLoS Pathog 2009;5:e1000689.
58. Kao C-Y, Los FCO, Huffman DL, Wachi S, Kloft N, Husmann M, Karabrahimi V, Schwartz J-L, Bellier A, Ha C, et al. Global functional analyses of cellular responses to pore-forming toxins. PLoS Pathog 2011;7:e1001314.
59. Los FCO, Kao C-Y, Smitham J, Mcdonald KL, Ha C, Peixoto CA, Aroian RV. RAB-5- And RAB-11-dependent vesicle-trafficking pathways are required for plasma membrane repair after attack by bacterial poreforming toxin. Cell Host Microbe 2011;9:147-157.
60. Kloft N, Neukirch C, Bobkiewicz W, Veerachato G, Busch T, von Hoven G, Boller K, Husmann M. Pro-autophagic signal induction by bacterial pore-forming toxins. Med Microbiol Immunol (Berl) 2010; 199:299-309.
61. Husmann M, Dersch K, Bobkiewicz W, Beckmann E, Veerachato G, Bhakdi S. Differential role of p38 mitogen activated protein kinase for cellular recovery from attack by pore-forming S. aureus alpha-toxin or streptolysin O. Biochem Biophys Res Commun 2006;344:1128-1134.